IQVIA Holdings Inc (NYSE: IQV) is a life sciences data, technology, and contract research organization that provides data analytics, clinical research, and commercial services to the pharmaceutical, biotechnology, and medical device industries. It generates revenue through long-term service contracts covering clinical trial management, real-world evidence, technology platforms, and healthcare data subscriptions. The 10-K filed 2026-02-17 (accession 000162828026008322) for the fiscal year ended discloses that most contracts may be terminated on short notice, indicating a mix of multi-year engagements and shorter-term arrangements. IQVIA's moat derives from proprietary healthcare data assets and switching costs embedded in clinical and commercial outsourcing relationships. The company cautions that data suppliers could restrict access or refuse to license data, which underscores how central third-party data sourcing is to its business model. Operations span international markets, with exposure to currency fluctuation and geopolitical risk noted as material factors.

Revenue model

Service contracts covering clinical research outsourcing, healthcare data subscriptions, and technology platform access. Contracts are primarily fee-for-service or subscription arrangements; most can be terminated on short notice per the FY2025 10-K filing.

Products and services

Clinical trial management and contract research services, real-world evidence analytics, healthcare data and technology platforms, and commercial outsourcing services for life sciences clients.

Customers and end markets

Pharmaceutical, biotechnology, and medical device companies. The filing notes risk from loss or delay of large client contracts and an inability to enter new contracts, indicating meaningful client concentration risk, though specific customer concentration percentages are not supported by the excerpts.

Value-chain role

Outsourced research and data intermediary sitting between life sciences manufacturers and regulatory/commercial endpoints. Aggregates third-party healthcare data and delivers analytics, clinical execution, and commercial services.

Geographic exposure

International operations with exposure to currency risk and international conflict noted as material business disruption factors. Specific country or regional revenue splits are not supported by the filing excerpts provided.

Source: SEC 10-K, filed 2026-02-17

Industry: Services-Commercial Physical & Biological Research Peers: Agilent Technologies Inc Avantor Inc Danaher Corp Revvity Inc Illumina Inc Mettler-toledo International Inc Thermo Fisher Scientific Inc West Pharmaceutical Services Inc Waters Corp